| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2014: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2013: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
Fiscal Year 2012: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
|---|
| Outline of Final Research Achievements |
We have established that metabolic tumor volume of primary tumor is an independent prognostic factor of laryngectomy-free survival and overall survival in patients with locally advanced laryngeal or hypopharyngeal cancer who are treated with chemoradiotherapy in the setting of larynx preservation. On the other hand, we subcutaneously transplanted surgically excised specimens of hypopharyngeal cancer (F0) into immunodeficient mice, and allowed them to grow to mass (F1). We comprehensively analyzed proteins overexpressed in F1 compared with F0, and identified glucose transporter 1 (GLUT1). A series of in vitro experiments revealed that GLUT1 conferred radioresistance on cells. These results indicate that therapy targeting glucose metabolism will serve to improve clinical outcome of locally advanced laryngeal or hypopharyngeal cancer with radioresistance.
|
